Suchergebnisse - "Kumar, Honnavalli Yogish"

PubPharm (6)

1

An Overview of CDK Enzyme Inhibitors in Cancer Therapy

enthalten in: Current cancer drug targets | 2023

von Mounika, P. | Gurupadayya, B. | Kumar, H. | +1

2

Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents

enthalten in: Molecular diversity | 2022

von Kumar, H. | Murumkar, P. | Srinivasan, B. | +2

3

Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents

enthalten in: Molecular diversity | 2021

von Kumar, H. | Murumkar, P. | Srinivasan, B. | +2

4

Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents

enthalten in: Molecular diversity | 2021

von Kumar, H. | Murumkar, P. | Srinivasan, B. | +2

5

CDK4/6 inhibitors : a brief overview and prospective research directions

enthalten in: RSC advances | 2021

von Adon, T. | Shanmugarajan, D. | Kumar, H.

6

Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules

enthalten in: Bioorganic & medicinal chemistry | 2020

von Ramya, K. | Suresh, R. | Kumar, H. | +2

1
[1]